Pharmaceutical giant GlaxoSmithKline is considering selling iconic drink brands Lucozade and Ribena “to ensure their continued growth” following a drop in operating profits at the company in 2012.
The drugs firm said it was placing the brands under review and would consider all strategic options which may see the products repositioned, partnered with another company, or sold off. Glaxo said: “These brands are iconic and the review will look at the best ways to ensure their continued growth.” The announcement came as Glaxo…
You’ve reached your free article limit for this month. Subscribe for free to continue reading and unlock full access.
Already a subscriber? Login
